Anti-cytokine therapy and plasma DNA in patients with rheumatoid arthritis.
Lucia LaukováBarbora KonečnáBarbora VlkováVanda MlynárikováPeter CelecEmőke ŠteňováPublished in: Rheumatology international (2018)
Treatment with bDMARDs decreases plasma ecDNA of both nuclear and mitochondrial origin. Dynamics of ecDNA is slower than dynamics of standard clinical markers. Therefore, it is likely to be not useful for monitoring of the disease progress, at least for RA.